Adult Acute Myeloid Leukemia
15
4
4
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia